Assessment of Weight Loss With the Intragastric Balloon in Patients With Different Degrees of Obesity

Nunes, Giovana Barros; Pajecki, Dênis; Melo, Maria Edna de; Mancini, Márcio C.; Cleva, Roberto de; Santo, Marco Aurélio

doi:10.1097/sle.0000000000000440

Cited by 16 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the total group of patients, the mean weight loss was 19.13 kg, %TWL was 18.42, % EWL was 65.66 and BMI decreased 6.85 kg/m 2 . These results are similar to those observed by Nunes et al (2017) [12] (%TWL of 18.9 and decrease in BMI of 6.76 kg/m 2 ) and are slightly superior to those observed in several other studies [13][14][15][16][17][18][19][20] and in two meta-analyses [21,22]. This greater decrease in body weight could be partly attributed to the balloon volume.…”

Section: Discussionsupporting

confidence: 91%

“…Fernandes et al (2016) [26] also observed a significantly higher %EWL in the group with lower baseline BMI (26 -30 kg/m 2 ) compared to the group with higher BMI (> 30 kg/m 2 ) (96% vs. 41%, respectively). Similarly, Nunes et al (2017) [12] and Al-Sabah et al (2016) [18] observed higher %EWL in the group of individuals with lower BMI at baseline. Although %EWL was greater in the subjects presenting pre-obesity, the %TWL was similar across the different degrees of overweight in our participants.…”

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

Intragastric Balloon: A Retrospective Evaluation of 5,874 Patients on Tolerance, Complications, and Efficacy in Different Degrees of Overweight

Zotarelli-Filho¹

2020

Preprint

View full text Add to dashboard Cite

Background: Endoscopic methods, especially the intragastric balloon (IGB), have been shown to be effective for the treatment of excess weight. This study aimed to assess the tolerance, complications and efficacy of excess weight treatment with a nonadjustable IGB during 6 months. Methods: A total of 5,874 patients treated with a liquid filled IGB (600-700mL) and followed up by a multidisciplinary team were evaluated. Participants presented an initial body mass index (BMI) [?]25 kg/m 2 and were stratified according to sex and degree of overweight (pre-obesity and obesity grade I, II and III). Results: The incidence of complications was 7.32% (n=430): 6.10% (n=357) early IGB removal, 0.20% (n=12) gas production inside the balloon, 0.54% (n=32) leakage, 0.32% (n=19) pregnancy, 0.07% (n=4) gastric perforation, 0.05% (n=3) upper digestive bleeding, 0.01% (n=1) Wernick Korsakoff syndrome due to excessive vomiting, 0.02% each (n=1) pancreatitis and esophagus perforation. The 5,444 remaining patients (4081 women, 38±38years) presented a weight loss of 19.13±8.86kg and a BMI decreased significantly (p<0.0001) (36.94±5.67 vs. 30.08±5.06 kg/m 2 ). The % total weight loss (%TWL) was 18.42±7.25% and % excess weight loss (%EWL) 65.66±36.24%. The treatment success rate (%TWL[?]10%) was 85%. The %EWL was higher in the pre-obese group (122.19%), followed by obesity grades I (76.67%), II (56.01%) and III (45.45%), with p<0.0001 for each group. %EWL was higher in women (69.71%) than in men (53.39), with p<0.0001 for each group. There was also a statistical difference between the TWL and EWL groups, with p<0.001 for all analyzes. Conclusion: Endoscopic IGB treatment for excess weight is an excellent therapeutic option for patients with different degrees of overweight.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 74%

Intragastric Balloon: A Retrospective Evaluation of 5,874 Patients on Tolerance, Complications, and Efficacy in Different Degrees of Overweight

Zotarelli-Filho¹

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The efficacy of IGB therapy in subjects with a BMI >27–35 kg/m 2 , who may not qualify for formal bariatric surgery, has been demonstrated [ 24 ]. A BMI cut-off of >27 kg/m 2 was therefore chosen for patient selection in this unit.…”

Section: Methodsmentioning

confidence: 99%

Outcomes following Serial Intragastric Balloon Therapy for Obesity and Nonalcoholic Fatty Liver Disease in a Single Centre

Nguyen

Gan

et al. 2017

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Background The incidence of nonalcoholic fatty liver disease (NAFLD) continues to parallel the rise in obesity rates. Endobariatric devices such as the intragastric balloon (IGB) may provide an alternative treatment option. Methods Outcomes following IGB treatment in 135 patients with obesity and NAFLD (mean baseline weight 117.9 kg; BMI 41.7 kg/m2; HOMA-IR 3.6) were retrospectively examined. Clinical, anthropometric, and biochemical changes were analysed at six months and after consecutive treatment with two and three serial IGBs. Results After six months, significant changes were seen with weight and BMI (mean reductions of 11.3 kg and 4.1 kg/m2, resp., p < 0.01 for both). Significant improvements were also seen with ALT, GGT, and HOMA-IR, with all changes corresponding with weight loss. Forty-eight patients received two IGBs, and 20 were treated with three serial IGBs. The greatest amount of total weight loss was observed after the first 6 months (mean weight lost 7.4 kg, versus 3.6 kg and 1.9 kg with two and three IGBs, resp.). Conclusions IGB therapy is an effective, alternative nonsurgical means for weight loss in the management of obesity and NAFLD over the short term, with greatest outcomes observed after six months. Improvements in insulin resistance and hepatic transaminases correlated with weight change.

show abstract

“…Given the high cost, complication risk and invasiveness of bariatric surgery, endoscopic treatment such as intragastric balloon (IB) is sometimes presented as a safer and lower-cost option for weight reduction (Hurt et al 2017). IBs are generally placed in the stomach endoscopically to reduce gastric capacity, enhance feelings of fullness and induce weight loss (Hurt et al 2017, Nunes et al 2017, Tate & Geliebter 2017. The IBs are removed after 6 months, as the risk of balloon deflation and possible migration increases substantially after this period (Hurt et al 2017, Nunes et al 2017, Tate & Geliebter 2017).…”

Section: Introductionmentioning

confidence: 99%

Use of an intragastric balloon for management of obesity in a dog

Védrine

Fernandes

Gérard

et al. 2020

J of Small Animal Practice

View full text Add to dashboard Cite

While various bariatric surgeries are commonplace in obesity medicine for humans, these techniques have not been commonly used in veterinary medicine. A technique used in humans consists in endoscopically placing an intragastric balloon. The intragastric balloon takes volume in the stomach causing a feeling of satiety and reducing food intake. A 57.6 kg, 9-year-old neutered female Labrador dog with chronic hypothyroidism was presented for overweight management. Combined levothyroxine treatment and dietary management with specific alimentation for obesity had failed to control overweight. An intragastric balloon was placed endoscopically in the stomach to allow the reduction of the gastric capacity and resulted in effective weight loss. The dog weight decreased to 40.9 kg at the time of intragastric balloon removal 198 days after placement. Further research including a larger sample size and long term follow-up is required to establish safety and effectiveness of this procedure.

show abstract

Assessment of Weight Loss With the Intragastric Balloon in Patients With Different Degrees of Obesity

Abstract: IGB provided sustained weight loss in patients who remained in dietary follow-up for 1 year.

Cited by 16 publications

References 19 publications

Intragastric Balloon: A Retrospective Evaluation of 5,874 Patients on Tolerance, Complications, and Efficacy in Different Degrees of Overweight

Intragastric Balloon: A Retrospective Evaluation of 5,874 Patients on Tolerance, Complications, and Efficacy in Different Degrees of Overweight

Outcomes following Serial Intragastric Balloon Therapy for Obesity and Nonalcoholic Fatty Liver Disease in a Single Centre

Use of an intragastric balloon for management of obesity in a dog

Contact Info

Product

Resources

About